Skip to main content

News

February 08, 2020
Intraoperative molecular imaging used to illuminate and target non-small-cell lung cancer shows improved outcomes for 26% of patients in multi-institutional Phase 2 clinical trial. WEST LAFAYETTE, Ind.
October 11, 2019
As liver therapy continues to rapidly evolve, the Symposium on Clinical Interventional Oncology featured a morning session updating attendees on changes that have occurred in recent months.
October 11, 2019
Areas ranging from immuno-oncology to artificial intelligence are poised to shape the future of care. The first day of the Symposium on Clinical Interventional Oncology featured a session focusing on emerging trends in interventional oncology. 
October 11, 2019
Friday, October 11, 2019 (Miami, FL) — The first day of the Symposium on Clinical Interventional Oncology (CIO) explored radioembolization using Y90 in detail.
October 10, 2019
Addressing the needs of physicians new to the interventional oncology (IO) field, the Symposium on Clinical Interventional Oncology (CIO) opened its first day with a pre-conference session focusing on IO fundamentals.
October 09, 2019
CGP Obtains a 12-Month Option to Offer to Acquire the Remaining Shares of OncoSec at the Greater of $4.50 Per Share or 110% of the Market Price
September 19, 2019
Leading the effort to connect the interventional oncology community, HMP, a leading health care event and education company, announced today the launch of the new IO Learning.
September 13, 2019
Torpedo™ Device Includes Pre-Shaped, Pre-Loaded Gelatin Foam, Removing Need for Manual Shaping and Loading
August 19, 2019
MARLBOROUGH, Mass., Aug. 19, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously announced scheme of arrangement. BTG develops and…
June 28, 2019
On May 10, 2019, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously…
June 26, 2019
WOBURN, Mass. (June 20, 2019) –– Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced delivery of the 100,000th patient dose of SIR-Spheres® Y-90 resin microspheres, a treatment for patients with liver cancer.*…
Back to Top